Altogether, our results illustrate a strong pro‐malignant role of the integrin‐FAK axis in CRC and provide crucial pathological and biological rationale for FAK/MYC‐based co‐targeting as a novel therapeutic strategy. The gene discussed is PTK2; the disease is colorectal carcinoma.